Stuttgart

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis3 trials
• Heart failure2 trials
• Prostate cancer2 trials
• Chronic myeloid leukaemia1 trial
• Coronary artery disease1 trial
• Familial hypercholesterolaemia1 trial
• Metastatic breast cancer1 trial
• Peripheral artery disease1 trial
• Sickle cell disease1 trial

Phase

• Phase 32 trials
• Phase 1/21 trial
• Phase 21 trial
• Phase 41 trial

Status

• Completed6 trials
• Active, not recruiting3 trials
• Recruiting2 trials

Lead sponsor

• Novartis Pharmaceuticals11 trials

Running trials

• Recruiting

  A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

  NCT07226986· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

  NCT06551519· Novartis Pharmaceuticals· Source

• Recruiting

  Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

  NCT06517719· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

  NCT05344469· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

  NCT03814746· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer2 recruiting

Closed trials

• Completed

  Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care

  NCT06004453· Novartis Pharmaceuticals· Source

• Completed

  Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies

  NCT05566756· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

  NCT05192941· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

  NCT03785405· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

  NCT06311383· Novartis Pharmaceuticals· Source

• Completed

  Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

  NCT01784068· Phase 2· Novartis Pharmaceuticals· Source